Implementing a Pediatric Camp Clinical for Pre-Licensure Education.

: This article describes the implementation and outcomes of a pediatric clinical education pilot project at a weekend overnight camp for children with special needs. Nine junior-level baccalaureate students participated in the immersion experience. The course skill inventory, an instructor-led postconference, a focus group session, and online forum entries were used to evaluate the experience.

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Dengue vaccine development has reached a major milestone with the initiation, in 2010, of the first phase III clinical trial to investigate the Sanofi Pasteur CYD tetravalent dengue vaccine (TDV). The CYD TDV candidate is composed of four recombinant, live, attenuated vaccines (CYD-1-4) based on a yellow fever vaccine 17D (YFV 17D) backbone, each expressing the pre-membrane and envelope genes of one of the four dengue virus serotypes. The vaccine is genetically and phenotypically stable, non-hepatotropic, less neurovirulent than YFV 17D, and does not infect mosquitoes by the oral route.